Sandoz Gains EU Approval for Ranluspec, Enhancing Biosimilars Position

Sandoz Group AG announced that the European Commission approved Ranluspec® (ranibizumab) for treating neovascular (wet) age-related macular degeneration (nAMD) and other retinal disorders. This approval is pivotal due to the significant number of individuals in key markets affected by these conditions.

The launch of Ranluspec is anticipated in the second half of 2026. This could significantly increase patient access to crucial treatments across Europe. Developed by Lupin, Ranluspec matches the efficacy and safety of the reference medicine, Lucentis®.

The announcement reinforces Sandoz's leadership in the biosimilars market and aligns with its strategy to capitalize on the projected USD 320 billion biosimilar-market opportunity over the next decade. It follows their recent launch of Afqlir® in ophthalmology and strengthens their market presence.